Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
62332-0565-90 62332-0565 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0566-30 62332-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0566-90 62332-0566 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0567-30 62332-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0567-90 62332-0567 ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 9, 2021 In Use
62332-0618-31 62332-0618 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
62332-0619-31 62332-0619 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
62332-0620-05 62332-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0621-17 62332-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0622-50 62332-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0650-05 62332-0650 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 22, 2022 In Use
62332-0650-10 62332-0650 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 22, 2022 In Use
62332-0659-02 62332-0659 Carmustine Carmustine Chemotherapy Alkylating Agent Nitrosourea Intravenous Oct. 20, 2023 In Use
62332-0678-02 62332-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 28, 2023 In Use
62332-0678-10 62332-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 28, 2023 In Use
62332-0678-16 62332-0678 Docetaxel Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 28, 2023 In Use
62332-0730-31 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
62332-0730-36 62332-0730 METHOTREXATE METHOTREXATE 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral June 4, 2024 In Use
62332-0751-50 62332-0751 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous March 3, 2023 In Use
62332-0779-31 62332-0779 Fluorouracil Fluorouracil 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Oct. 18, 2023 In Use
62332-0813-50 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
62332-0813-63 62332-0813 Nelarabine NELARABINE 5.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Aug. 1, 2024 In Use
62484-0020-01 62484-0020 Purixan Purixan 20.0 mg/mL Chemotherapy Antimetabolite Purine Analog Oral April 28, 2014 In Use
62484-0020-02 62484-0020 Purixan Purixan 20.0 mg/mL Chemotherapy Antimetabolite Purine Analog Oral April 28, 2014 In Use
62559-0173-31 62559-0173 Nilutamide Nilutamide 150.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Oral July 18, 2016 In Use

Found 10,000 results in 8 milliseconds — Export these results